R-Pharm and Flex Databases to Present Poster on Data Empowered Decision Making at DIA 2014 50th Annual Meeting
Flex Databases, a company specializing in software and consulting services for the healthcare industry, has announced that R-Pharm, a Russian pharmaceutical company, will be presenting a poster on data empowered decision making at DIA 2014 50th Annual Meeting in San Diego, US. The poster has been jointly prepared by R-Pharm and Flex Databases and reflects the experience of implementation of the Flex Databases software platform by R-Pharm.
"There were several questions we needed to solve while scaling our activities and growing the number of projects at R-Pharm", says Mikhail Samsonov, Chief Medical Officer at R-Pharm. "How do we keep track of all our projects, regardless of what stage or functional area they belong to? How do we make sure we maintain the quality of work as new people join? And, most importantly, how do we obtain data for decision making, while not spending unreasonably high amount of time to produce and consolidate reports?
"Flex Databases offered answers to all these questions. We now have a platform which provides a project library and a flexible workflow tool, enabling us to obtain real time project status information and guide activities of our employees at each step. The platform is used to manage and implement projects from a variety of functional areas (Chemistry Manufacturing Control, due diligence, clinical development and operations, regulatory and pharmacovigilance). We are keen to share the knowledge we generated as we believe the industry as a whole could benefit from a move to company-wide platforms, as benefits far outweigh the investment needed. Moreover, growing biotech companies and startups could especially benefit using such approach.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance